Simplify diabetes management for your patients
Omnipod® 5 Automated Insulin Delivery
The first wearable, tubeless, hybrid closed loop system with sensor integration (Dexcom G7, Dexcom G6†, and Abbott FreeStyle Libre 2 Plus) for your patients with type 1 diabetes (T1D) aged 2 years and older.
System Components:
Controller + Pod + CGM/Sensor
Compatible with Dexcom G7, Dexcom G6†, and FreeStyle Libre 2 Plus
- Your patients can experience the freedom of automated insulin delivery with their preferred glucose sensor and Omnipod 5
- SmartAdjust™ Technology adjusts basal insulin delivery, every five minutes, so you don’t have to.** It proactively helps to correct highs and protect from lows.1,2
- Improved HbA1c and time in range across age groups vs prior therapy, while time in hypoglycaemia remained low1,2
Omnipod 5’s Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ is Omnipod 5’s automated insulin delivery algorithm. It adjusts basal insulin automatically so there is no need to continuously fine-tune basal settings. The system uses recent total daily insulin history to adapt to changes throughout life like changes in weight, growth and aging.**
Watch this short video to learn more about the technology and how it works.
Want to get hands-on understanding of our intuitive Omnipod 5 AID system?
Try the free simulator app on your smartphone
We believe in freedom of choice
Omnipod 5 and Omnipod DASH® Pods are partially subsidised and listed on the NDSS.
Access to Omnipod 5 and Omnipod DASH® is available with private health insurance similar to other insulin pump systems; OR by paying a no lock-in subscription fee (Pay as you Pod) to Insulet Australia.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod.
†Dexcom is in the process of discontinuing Dexcom G6 to focus on delivering the next generation of Sensor. Omnipod 5 will continue to support integration with Dexcom G6 for as long as this sensor remains available. For more information, please visit www.dexcom.com or contact Dexcom support.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Median time in hyperglycemic range (>10.0 mmol/L) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs. 29.7%, P<0.0001, respectively. Median time in hypoglycemic range (<3.9 mmol/L) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P 0.8153, respectively. Study funded by Insulet. Study materials provided by Insulet
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time in hyperglycemic range (>10.0 mmol/L) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs 29.5%, P<0.0001, respectively. Median time in hypoglycemic range (<3.9 mmol/L) as measured by CGM in children ST vs. 3-mo Omnipod 5: 2.19% vs. 1.94%, P = 0.0204. Study funded by Insulet. Study materials provided by Insulet.
